

4 January 2018

ASX Code: MXC

Official Launch Confirmed - MGC Derma's CBD Herbal Cream for Relief of Psoriasis Symptoms

A
S
X

R
E
L
E
A
S
E

- MGC Pharmaceuticals' (MXC) MGC Derma Division has today officially launched its first Derma Plus product, for relief of psoriasis symptoms
- The Derma Plus product is the CBD Herbal Repair Cream, specifically developed for relief of mild forms of psoriasis
- The Derma Plus range, comprising 3 products, completed successful clinical tests at a leading independent European dermatological clinic during H2 2017
- Results from the independent testing confirmed the product's efficacy for the relief of a range of highly irritated or inflamed skin conditions
- The Herbal Repair Cream is now available for sale through MGC Derma's website <https://mgcderma.com/cbd-herbal-repair-cream>, and existing eCommerce platforms
- The two additional Derma Plus products for relief from acne and dermatitis conditions, the Herbal Balm and Herbal Replenish Cream, are also planned for launch during Q1 2018

MGC Pharmaceuticals Ltd (ASX: MXC or "the Company") is pleased to announce that its MGC Derma division has now officially launched its first Derma Plus product.

The product is the Herbal Repair Cream which utilises proprietary cannabidiol (CBD) compounds and is used for the daily relief of mild forms of psoriasis. The psoriasis symptoms successfully treated through the independent tests completed to date include effective reduction of skin irritation (by 69 % after 4 weeks of evaluation), and treatment of skin itchiness, flaking and severe dryness.

Independent experts estimate that the global market for psoriasis treatment, which was worth US\$7.8 bn in 2015, is projected to expand at a compound annual growth rate (CAGR) of 5.10% during the period for 2016 to 2024 and attain a value of US\$12.1B by the end of the forecast period. *Source: Transparency Market Research Psoriasis Treatment Market*

The Herbal Repair Cream is as of today available for sale to MGC Derma customers globally through their existing commercial distribution channels and eCommerce platforms, including the MGC Derma website: <https://mgcderma.com/cbd-herbal-repair-cream> and throughout the European Union, North America and Australasia where the product is approved for sale.



Successful Independent European Clinical Testing

As detailed in Company announcements during 2017, the product has been successfully clinically tested to confirm its efficacy in persons with psoriasis by Dr Rok Devjak, MD PhD, at the leading dermatological clinic in Slovenia. Results from the clinical test program showed that the Herbal Repair Cream helps to significantly reduce itching, flaking and dryness as well as soothe, soften and comfort sensitive skin and reduce the symptoms of dry skin for people with psoriasis.

According to the International Federation of Psoriasis Association, approximately 5.0% people suffer from one or more forms of psoriasis, globally. In the U.S. alone, the condition affects nearly 7.5 million people, which is roughly 2.0% of the population. Moreover, approximately 100,000 new cases are registered and reported every year. *Source: Grand View Research, Market Research Report, Psoriasis Drugs Market Analysis*

Two additional products from the Derma Plus range are still expected to be made available for sale early this year. The additional products are: a Herbal Replenishing Cream which can be used for the daily care of mild seborrheic dermatitis and a Herbal Repair Balm which can be used for the daily care of oily and acne prone skin.

MGC Derma Division is a 51:49 joint venture between MGC Pharmaceuticals and well-credentialed cosmetic manufacturer Dr. M. Burstein Ltd.

-- Ends --

For further information, please contact:

Media Enquiries

Harrison Polities
Media and Capital Partners
+61 409 623 618
harrison.polites@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based specialist medical cannabis biopharma company with many years of technical, clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to be a global leader in phytocannabinoid-based medicine within the biopharmaceutical medical markets in Europe, Australasia and North America.

Follow us through our social media channels   